Reem El Kabbout
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reem El Kabbout has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- François Potus
Pulmonary Hypertension Research Group, Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada
2 shared publications - Olivier Boucherat
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada (M.M., O.B., S.P., S.B., F.P.).
2 shared publications - Sandra Martineau
Pulmonary Hypertension Research Group, Centre de Recherche Universitaire de Cardiologie et de Pneumologie de Québec, Canada (Y.G., S.-E.L., M.M., C.T., M.B., S.B.-B., S.M., A.B., A.P., M.F., J.P., F.P., S.P., O.B., S.B.).
2 shared publications - Steeve Provencher
PAH Research Group, Institut Universitaire de Cardiologie et Pneumologie de Québec Research Center, Department of Medicine, Université Laval, Quebec City, Québec, Canada
2 shared publications - Sébastien Bonnet
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada (M.M., O.B., S.P., S.B., F.P.).
2 shared publications - Yann Grobs
Pulmonary Hypertension Research Group, Centre de Recherche Universitaire de Cardiologie et de Pneumologie de Québec, Canada (Y.G., S.-E.L., M.M., C.T., M.B., S.B.-B., S.M., A.B., A.P., M.F., J.P., F.P., S.P., O.B., S.B.).
2 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (7) , 516-533
Breast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.
- 17 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (7) , 516-533
Open AccessBreast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.
- Top Cited PapersOpen Access
- 22 April 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (16) , 1162-1183
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored. METHODS: The expression of the RGD (arginylglycylaspartic acid)–binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling. RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)–regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices. CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.
- 22 April 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (16) , 1162-1183
Top Cited PapersOpen AccessExploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored. METHODS: The expression of the RGD (arginylglycylaspartic acid)–binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling. RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)–regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices. CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1608
Increased DNA Methylation: A Potential Therapeutic Target in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is marked by vasoconstriction and remodeling of pulmonary arteries, driven by excessive proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). This contributes to disease progression, with current treatments showing limited success. DNA methylation (DNAm) has been linked to pro-proliferative and survival phenotypes, suggesting its role in PAH. We hypothesized that increased DNAm contributes to the survival and proliferation of PASMCs in PAH, positing DNAm targeting could offer therapeutic benefits. We observed a global DNAm increase and elevated DNA methyltransferase levels in PASMCs from PAH patients and in three preclinical models (monocrotaline, sugen hypoxia, Fawn hooded rats), indicating a potential mechanism for disease exacerbation. In vitro, PAH-PASMCs showed elevated DNAm and DNA methyltransferase levels, with reduced DNA demethylase expression. Treatment with the hypomethylating agent Zebularine led to dose-dependent reductions in PASMC proliferation and increased apoptosis, supported by transcriptomic analyses suggesting involvement of cell cycle and mitosis regulation. In vivo, Zebularine treatment improved PAH hemodynamics, decreased PASMC methylation and proliferation, and reduced vascular remodeling in rodent models, highlighting the drug's potential for reversing PAH pathology. Our research links increased DNAm with PAH progression and suggests targeting DNAm, as demonstrated by Zebularine's efficacy, could be a promising therapeutic strategy, addressing underlying molecular alterations and offering hope for more effective treatments.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1608
Increased DNA Methylation: A Potential Therapeutic Target in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is marked by vasoconstriction and remodeling of pulmonary arteries, driven by excessive proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). This contributes to disease progression, with current treatments showing limited success. DNA methylation (DNAm) has been linked to pro-proliferative and survival phenotypes, suggesting its role in PAH. We hypothesized that increased DNAm contributes to the survival and proliferation of PASMCs in PAH, positing DNAm targeting could offer therapeutic benefits. We observed a global DNAm increase and elevated DNA methyltransferase levels in PASMCs from PAH patients and in three preclinical models (monocrotaline, sugen hypoxia, Fawn hooded rats), indicating a potential mechanism for disease exacerbation. In vitro, PAH-PASMCs showed elevated DNAm and DNA methyltransferase levels, with reduced DNA demethylase expression. Treatment with the hypomethylating agent Zebularine led to dose-dependent reductions in PASMC proliferation and increased apoptosis, supported by transcriptomic analyses suggesting involvement of cell cycle and mitosis regulation. In vivo, Zebularine treatment improved PAH hemodynamics, decreased PASMC methylation and proliferation, and reduced vascular remodeling in rodent models, highlighting the drug's potential for reversing PAH pathology. Our research links increased DNAm with PAH progression and suggests targeting DNAm, as demonstrated by Zebularine's efficacy, could be a promising therapeutic strategy, addressing underlying molecular alterations and offering hope for more effective treatments.